I her by certify that this paper (along with any paper referred to as being attached or exclosed) is being deposited with the U.S. Postal Service on the date shown with sufficient postage as First Class Mail, in an envelope addressed to: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA **2**2313-1450. Signature: Maura 4

Docket No.: 104831-0002-103

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Dated: September 24, 2007

Chang et al.

Application No.: 10/657,383

Confirmation No.: 9375

Art Unit: 1623 Filed: September 8, 2003

METHOD FOR ENHANCING THE For:

EFFECTIVENESS OF CANCER

THERAPIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Examiner: L. C. Maier

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37) CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in a communication from related U.S. Patent

Docket No.: 104831-0002-103 Application No.: 10/657,383

Application No. 10/408,723 (copy enclosed) not more than three months prior to the filing of this

Information Disclosure Statement. The Examiner is also requested to consider the Office Action.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents

and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent

literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall

not be construed to mean that a search has been made or that no other material information as

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information

Disclosure Statement shall not be construed to be an admission that any patent, publication or other

information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98

and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee

set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees

filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed

in this application by this firm) to our Deposit Account No. 18-1945, under Order No. 104831-

0002-103. A duplicate copy of this paper is enclosed.

Dated: September 25, 2007

Respectfully submitted,

Jesse A. Fecker, Ph.D.

Registration No.: 52,883

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

2